Vaxcyte (PCVX) Projected to Announce Earnings on Tuesday

Vaxcyte (NASDAQ:PCVX) is anticipated to announce its Q3 2026 results after the market closes on Tuesday, November 3rd. Analysts expect the company to announce earnings of ($2.11) per share and revenue of $12.50 million for the quarter. Interested persons may visit the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 4:00 PM ET.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($1.97) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.06) by $0.09. During the same quarter in the prior year, the company earned ($1.22) EPS. On average, analysts expect Vaxcyte to post ($7.47) EPS for the current fiscal year and ($6.36) EPS for the next fiscal year.

Vaxcyte Stock Down 0.8%

Shares of PCVX stock opened at $59.97 on Tuesday. Vaxcyte has a one year low of $39.87 and a one year high of $90.75. The stock has a 50-day moving average of $61.53 and a 200-day moving average of $56.54.

Insider Buying and Selling at Vaxcyte

In other news, CAO Elvia Cowan sold 19,000 shares of Vaxcyte stock in a transaction that occurred on Monday, October 5th. The shares were sold at an average price of $86.74, for a total value of $1,648,060.00. Following the completion of the sale, the chief accounting officer directly owned 27,860 shares in the company, valued at approximately $2,416,576.40. The trade was a 40.55% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Harpreet Dhaliwal sold 17,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $55.00, for a total value of $935,000.00. Following the completion of the sale, the insider owned 76,756 shares of the company’s stock, valued at approximately $4,221,580. This trade represents a 18.13% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 74,692 shares of company stock valued at $5,308,175 over the last ninety days. Company insiders own 3.30% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. Cantor Fitzgerald reissued an “overweight” rating and set a $120.00 price target on shares of Vaxcyte in a research report on Monday, October 12th. Wall Street Zen raised Vaxcyte from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 8th. Bank of America cut their price objective on Vaxcyte from $133.00 to $130.00 and set a “buy” rating for the company in a research report on Monday, September 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vaxcyte in a research report on Friday, October 2nd. Finally, Needham & Company LLC raised their target price on shares of Vaxcyte from $110.00 to $122.00 and gave the stock a “buy” rating in a research note on Monday, October 5th. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $110.50.

Vaxcyte Company Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing vaccines designed to protect against serious bacterial diseases. The company is headquartered in San Carlos, California, and uses its proprietary cell-free protein synthesis and conjugation technologies to develop vaccine candidates intended to provide broad and durable immune protection.

Vaxcyte’s lead programs target pneumococcal disease, an infection caused by Streptococcus pneumoniae.